Latest Articles
A Look At BioNTech (BNTX) Valuation After Positive Phase 2 HER2 Endometrial Cancer Data - simplywall.st
A Look At BioNTech (BNTX) Valuation After Positive Phase 2 HER2 Endometrial Cancer Data simplywall.st
Published: April 12, 2026, 7:29 p.m.
Mocertatug Rezetecan Displays Early Efficacy, Tolerability in PROC and Endometrial Cancer - OncLive
Mocertatug Rezetecan Displays Early Efficacy, Tolerability in PROC and Endometrial Cancer OncLive
Published: April 12, 2026, 6:25 p.m.
Peer Support Helps Black Women With Endometrial Cancer Stay on Treatment - Cure Today
Peer Support Helps Black Women With Endometrial Cancer Stay on Treatment Cure Today
Published: April 12, 2026, 6:04 p.m.
BioNTech's Endometrial Cancer Data Signals Pivotal Pipeline Progress - AD HOC NEWS
BioNTech's Endometrial Cancer Data Signals Pivotal Pipeline Progress AD HOC NEWS
Published: April 12, 2026, 5:41 p.m.
Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer - OncLive
Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer OncLive
Published: April 12, 2026, 2:35 p.m.
GSK presents positive data for B7-H4-targeted ADC in gynecological cancers - GSK US
GSK presents positive data for B7-H4-targeted ADC in gynecological cancers GSK US
Published: April 12, 2026, 2:25 p.m.
GSK presents positive data for B7-H4-targeted ADC in gynecological cancers - GSK
GSK presents positive data for B7-H4-targeted ADC in gynecological cancers GSK
Published: April 12, 2026, 2:25 p.m.
Strong early data prompts GSK to plan five Phase 3 studies for gynecological cancer ADC - Endpoints News
Strong early data prompts GSK to plan five Phase 3 studies for gynecological cancer ADC Endpoints News
Published: April 12, 2026, 2:10 p.m.
BioNTech's Cancer Candidate Clears Path for FDA Filing - AD HOC NEWS
BioNTech's Cancer Candidate Clears Path for FDA Filing AD HOC NEWS
Published: April 12, 2026, 12:31 p.m.
Dr O'Cearbhaill on the Evaluation of REGN5668 in Recurrent Ovarian or Endometrial Cancer - OncLive
Dr O'Cearbhaill on the Evaluation of REGN5668 in Recurrent Ovarian or Endometrial Cancer OncLive
Published: April 12, 2026, 12:58 a.m.
Link copied to clipboard!